Anti-TNF-α Therapy for Extraintestinal Manifestations of Inflammatory Bowel Disease

TY - JOUR

T1 - Anti-TNF-α Therapy for Extraintestinal Manifestations of Inflammatory Bowel Disease

AU - Nielsen, Ole Haagen

AU - Bendtzen, Klaus

AU - Pedersen, Jannie

PY - 2015

Y1 - 2015

N2 - The introduction of biological tumor necrosis factor (TNF)-α inhibitors has transformed the paradigm for the treatment of inflammatory bowel disease (IBD), i.e. Crohn's disease and ulcerative colitis. The specific TNF inhibitors currently approved for patients with IBD are infliximab, adalimumab and certolizumab pegol for Crohn's disease refractory to conventional treatment and infliximab, adalimumab, and golimumab for ulcerative colitis. Additionally, many patients with IBD have extraintestinal manifestations, and biological TNF inhibitors have also been shown to be of therapeutic benefit for these patients. The present chapter highlights these indications.

AB - The introduction of biological tumor necrosis factor (TNF)-α inhibitors has transformed the paradigm for the treatment of inflammatory bowel disease (IBD), i.e. Crohn's disease and ulcerative colitis. The specific TNF inhibitors currently approved for patients with IBD are infliximab, adalimumab and certolizumab pegol for Crohn's disease refractory to conventional treatment and infliximab, adalimumab, and golimumab for ulcerative colitis. Additionally, many patients with IBD have extraintestinal manifestations, and biological TNF inhibitors have also been shown to be of therapeutic benefit for these patients. The present chapter highlights these indications.

U2 - 10.1159/000381607

DO - 10.1159/000381607

M3 - Journal article

AN - SCOPUS:84937906904

SN - 0302-0665

VL - 34

SP - 206

EP - 213

JO - Frontiers of Gastrointestinal Research

JF - Frontiers of Gastrointestinal Research

ER -